{"downloaded": true, "htmlmade": false, "full": {"id": "29795422", "source": "MED", "pmid": "29795422", "pmcid": "PMC6320344", "fullTextIdList": {"fullTextId": "PMC6320344"}, "doi": "10.1038/s41409-018-0228-z", "title": "Plerixafor in non-Hodgkin's lymphoma patients: a German analysis of time, effort and costs.", "authorString": "H\u00fcbel K, Ostermann H, Gla\u00df B, Noppeney R, Kron F, Kron A, Milkovich G, Mohty M.", "authorList": {"author": [{"fullName": "H\u00fcbel K", "firstName": "Kai", "lastName": "H\u00fcbel", "initials": "K", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Internal Medicine, University Hospital of Cologne, Cologne, Germany. kai.huebel@uni-koeln.de."}}}, {"fullName": "Ostermann H", "firstName": "H", "lastName": "Ostermann", "initials": "H", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Internal Medicine III, University of Munich, Munich, Germany."}}}, {"fullName": "Gla\u00df B", "firstName": "Bertram", "lastName": "Gla\u00df", "initials": "B", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Hematology, Oncology and Cancer Immunology, Helios-Klinikum Berlin-Buch, Berlin, Germany."}}}, {"fullName": "Noppeney R", "firstName": "Richard", "lastName": "Noppeney", "initials": "R", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Hematology, University Hospital Essen, Essen, Germany."}}}, {"fullName": "Kron F", "firstName": "Florian", "lastName": "Kron", "initials": "F", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany."}}}, {"fullName": "Kron A", "firstName": "Anna", "lastName": "Kron", "initials": "A", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany."}}}, {"fullName": "Milkovich G", "firstName": "Gary", "lastName": "Milkovich", "initials": "G", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "RJM Group, LLC, 13028 Smoketown Road, Woodbridge, VA, 22192, USA."}}}, {"fullName": "Mohty M", "firstName": "Mohamad", "lastName": "Mohty", "initials": "M", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Haematology, Saint-Antoine Hospital, Paris, France."}}}]}, "dataLinksTagsList": {"dataLinkstag": ["supporting_data", "altmetrics"]}, "journalInfo": {"issue": "1", "volume": "54", "journalIssueId": "2767015", "dateOfPublication": "2019 Jan", "monthOfPublication": "1", "yearOfPublication": "2019", "printPublicationDate": "2019-01-01", "journal": {"title": "Bone marrow transplantation", "ISOAbbreviation": "Bone Marrow Transplant", "medlineAbbreviation": "Bone Marrow Transplant", "NLMid": "8702459", "ISSN": "0268-3369", "ESSN": "1476-5365"}}, "pubYear": "2019", "pageInfo": "123-129", "abstractText": "Mobilization and collection of peripheral blood stem cells is part of the standard treatment procedure for non-Hodgkin's lymphoma patients eligible for high-dose chemotherapy with autologous stem cell transplantation. Mobilization is usually achieved with chemotherapy and/or cytokines, but plerixafor might be added in case of poor mobilization. Due to the high cost several institutions have developed their own management pathway to optimize use of plerixafor. Such models are however rarely generalizable; in a multi-center, European, non-interventional study, evaluating the impact of plerixafor in poor mobilizers, country specific differences in patient treatment and cost structure were obvious. For German centers, there was a non-significant reduction in the number of apheresis sessions carried out and in apheresis costs. In contrast to other European countries the majority of German Plerixafor patients were very poor mobilizing patients with initial CD34+\u00a0cell count\u2009\u2264\u200910/\u00b5l (40/51). In this group the number of apheresis sessions decreased from 2.1 to 1.6 sessions per patient (p\u2009=\u20090.01) and costs decreased from \u20ac6246 to \u20ac4758 (p\u2009=\u20090.01). Our results show that preemptive plerixafor use has a strong effect in poor mobilizers with an initial CD34+ cell count\u2009\u2264\u200910 cells/\u00b5l.", "affiliation": "Department of Internal Medicine, University Hospital of Cologne, Cologne, Germany. kai.huebel@uni-koeln.de.", "publicationStatus": "ppublish", "language": "eng", "pubModel": "Print-Electronic", "pubTypeList": {"pubType": ["Clinical Trial", "research-article", "Multicenter Study", "Journal Article"]}, "meshHeadingList": {"meshHeading": [{"majorTopic_YN": "N", "descriptorName": "Humans"}, {"majorTopic_YN": "Y", "descriptorName": "Lymphoma, Non-Hodgkin", "meshQualifierList": {"meshQualifier": [{"abbreviation": "BL", "qualifierName": "blood", "majorTopic_YN": "N"}, {"abbreviation": "EC", "qualifierName": "economics", "majorTopic_YN": "N"}, {"abbreviation": "TH", "qualifierName": "therapy", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "Y", "descriptorName": "Heterocyclic Compounds", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "N"}, {"abbreviation": "EC", "qualifierName": "economics", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Leukocyte Count"}, {"majorTopic_YN": "N", "descriptorName": "Hematopoietic Stem Cell Mobilization", "meshQualifierList": {"meshQualifier": {"abbreviation": "EC", "qualifierName": "economics", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Blood Component Removal", "meshQualifierList": {"meshQualifier": {"abbreviation": "EC", "qualifierName": "economics", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Time Factors"}, {"majorTopic_YN": "N", "descriptorName": "Adult"}, {"majorTopic_YN": "N", "descriptorName": "Aged"}, {"majorTopic_YN": "N", "descriptorName": "Middle Aged"}, {"majorTopic_YN": "N", "descriptorName": "Costs and Cost Analysis"}, {"majorTopic_YN": "N", "descriptorName": "Germany"}, {"majorTopic_YN": "N", "descriptorName": "Female"}, {"majorTopic_YN": "N", "descriptorName": "Male"}]}, "chemicalList": {"chemical": [{"name": "Heterocyclic Compounds", "registryNumber": "0"}, {"name": "plerixafor", "registryNumber": "S915P5499N"}]}, "subsetList": {"subset": {"code": "IM", "name": "Index Medicus"}}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1038/s41409-018-0228-z"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC6320344"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "pdf", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC6320344?pdf=render"}]}, "isOpenAccess": "Y", "inEPMC": "Y", "inPMC": "N", "hasPDF": "Y", "hasBook": "N", "hasSuppl": "Y", "citedByCount": "1", "hasData": "Y", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "N", "hasLabsLinks": "Y", "license": "cc by", "authMan": "N", "epmcAuthMan": "N", "nihAuthMan": "N", "hasTMAccessionNumbers": "Y", "tmAccessionTypeList": {"accessionType": "nct"}, "dateOfCompletion": "2020-01-22", "dateOfCreation": "2018-05-26", "firstIndexDate": "2018-05-26", "fullTextReceivedDate": "2020-07-10", "dateOfRevision": "2021-02-26", "electronicPublicationDate": "2018-05-24", "firstPublicationDate": "2018-05-24"}, "htmllinks": "https://europepmc.org/articles/PMC6320344", "abstract": "Mobilization and collection of peripheral blood stem cells is part of the standard treatment procedure for non-Hodgkin's lymphoma patients eligible for high-dose chemotherapy with autologous stem cell transplantation. Mobilization is usually achieved with chemotherapy and/or cytokines, but plerixafor might be added in case of poor mobilization. Due to the high cost several institutions have developed their own management pathway to optimize use of plerixafor. Such models are however rarely generalizable; in a multi-center, European, non-interventional study, evaluating the impact of plerixafor in poor mobilizers, country specific differences in patient treatment and cost structure were obvious. For German centers, there was a non-significant reduction in the number of apheresis sessions carried out and in apheresis costs. In contrast to other European countries the majority of German Plerixafor patients were very poor mobilizing patients with initial CD34+\u00a0cell count\u2009\u2264\u200910/\u00b5l (40/51). In this group the number of apheresis sessions decreased from 2.1 to 1.6 sessions per patient (p\u2009=\u20090.01) and costs decreased from \u20ac6246 to \u20ac4758 (p\u2009=\u20090.01). Our results show that preemptive plerixafor use has a strong effect in poor mobilizers with an initial CD34+ cell count\u2009\u2264\u200910 cells/\u00b5l.", "pdflinks": "https://europepmc.org/articles/PMC6320344?pdf=render", "journaltitle": "Bone marrow transplantation", "authorinfo": ["H\u00fcbel K", "Ostermann H", "Gla\u00df B", "Noppeney R", "Kron F", "Kron A", "Milkovich G", "Mohty M"], "title": "Plerixafor in non-Hodgkin's lymphoma patients: a German analysis of time, effort and costs."}